Pneumococcal conjugate vaccines (PCVs) reduce disease and colonization by the serotypes they cover. As of now, the Advisory Committee on Immunization Practices (ACIP) recommends that PCV15 and PCV20 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory ...

The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services ...

KLOSTERNEUBURG, Austria & ROCKVILLE, Md.--(BUSINESS WIRE)--VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics ...

On June 17, Merck received FDA approval for a vaccine designed to protect adults from pneumococcus, a type of bacteria that can cause serious disease, including pneumonia. The conjugate vaccine, ...

Tuesday, Vaxcyte, Inc. (NASDAQ:PCVX) released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company's 31-valent pneumococcal conjugate ...

—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...

Merck's shot, called Capvaxive, specifically protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease that can spread to other parts of the body and lead to ...

SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the ...

Eli Lilly has agreed to acquire three privately-held developers of vaccines for infectious diseases for a combined up-to-$3.83 billion cash, in deals intended to expand the acquisitive pharma giant’s ...

National-level CDC surveillance data shows CAPVAXIVE covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases, compared to approximately 52% covered by PCV20 ...

Stream NBC 5 for free, 24/7, wherever you are. Healthy adults can suffer from pneumococcal disease. But older patients and those with chronic or immunocompromising health conditions are at increased ...